The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
Ivan Arias de la RosaMaria Dolores López-MontillaCristobal Román-RodríguezCarlos Pérez-SánchezIgnacio Gómez-GarcíaClementina López-MedinaMaria Lourdes Ladehesa-PinedaMaria Del Carmen Ábalos-AguileraDesiree RuizAlejandra Maria Patiño-TrivesMaria Luque-TévarIsabel Añón-OñateMaria Jose Pérez-GalánRocio Guzmán-RuizMaria M MalagónRosario Lopez-PedreraAlejandro Escudero-ContrerasEduardo Collantes-EstévezNuria BarbarrojaPublished in: Journal of internal medicine (2022)
(1) Novel CVD-related proteins associated with clinical features could be emerging therapeutic targets in the context of PsA and (2) the pleiotropic action of apremilast could make it an excellent choice for the management of PsA patients with high CVD risk, targeting metabolic alterations and CVD-related molecules.